NCT00414765

Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma

Open-label Pharmacokinetic Trial of Aldesleukin (Rh-Interleukin-2 [IL-2]) Administered Intravenously to Subjects With Metastatic Renal Cell Carcinoma or Metastatic Melanoma With Immunologic Correlative Studies

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 26 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study evaluated the pharmacokinetics of aldesleukin in participants with metastatic renal cell cancer or metastatic melanoma.

Conditions

• Metastatic Renal Cell Carcinoma
• Metastatic Melanoma

Interventions

Type	Name	Description
DRUG	Aldesleukin

Timeline

• Start date: 2008-09-03
• Primary completion: 2010-03-28
• Completion: 2010-03-28
• First posted: 2006-12-22
• Last updated: 2021-06-08
• Results posted: 2021-06-08

Locations

4 sites across 1 country: United States

Regulatory

• FDA-regulated drug study